NCT06945887 Treatment of Desmoid Fibromatosis With Arterial Embolization
| NCT ID | NCT06945887 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Istituto Ortopedico Rizzoli |
| Condition | Desmoid Fibromatosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-07-01 |
| Primary Completion | 2028-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2025-07-01 with a primary completion date of 2028-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Desmoid fibromatoses are rare and locally aggressive mesenchymal tumors. The current scientific evidence regarding the efficacy and safety of the treatment of desmoid fibromatosis by arterial embolization is constituted by several retrospective and prospective studies. These studies report promising results through the use of chemoembolization, that is, arterial embolization using particles loaded with chemotherapy. Instead, the type of treatment we propose would consist of injection of embolizing material without the use of chemotherapy, based on the positive results we have consistently reported over the years on arterial embolization of musculoskeletal tumors.
Eligibility Criteria
Inclusion Criteria: * Patients of both sexes aged ≥ 12 years * Fibromatosis demsoid symptomatic and in active phase (documented growth at last follow-ups) * Patients not eligible for surgery or cryoablation * Patients who have had embolization surgery for fibromatosis desmoide from 01/01/2023 to date and all new patients listed for this type of treatment. * Signature of informed consent to the study Exclusion Criteria: * Patients with life expectancy \<3 months or severely impaired status functional status (ASA 4) * Patients with fibromatosis not in active phase, documented clinically and by investigations imaging (MRI, CT) * Patients with coagulation deficiency or plateletopenic disease * Patients with documented active infection * Incompatibility to performing MRI examination.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06945887 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, studying Desmoid Fibromatosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06945887 currently recruiting?
Yes, NCT06945887 is actively recruiting participants. Contact the research team at giancarlo.facchini@ior.it for enrollment information.
Where is the NCT06945887 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT06945887 clinical trial?
NCT06945887 is sponsored by Istituto Ortopedico Rizzoli. The trial plans to enroll 20 participants.